Bio-Rad Q3 2026: Non-GAAP EPS $2.65, GAAP Profit $458.6M on Sartorius Mark, Outlook Held
BIO sits 60% above its 52-week low of $236.73.
Summary
Bio-Rad's Q3 GAAP profit of $458.6 million was almost entirely a non-cash Sartorius mark-to-market gain. Core non-GAAP operating income rose to $83.7 million on flat sales, and full-year guidance was left unchanged.
Key Events · Earnings and Guidance · BIO
-
Q3 Sales Roughly Flat at $656.4M
Net sales rose 0.5% reported and 0.7% currency-neutral versus $653.0 million a year ago. Clinical Diagnostics grew 2.7% to $401.8 million, while Life Science fell 2.8% to $254.6 million.
-
GAAP Profit Is a Sartorius Mark, Not Operations
GAAP net income of $458.6 million ($17.02 per diluted share) was driven by a $588.2 million gain from the change in fair value of equity securities. GAAP operations lost $(49.7) million after $77.2 million of restructuring and a $49.8 million non-cash intangible impairment.
-
Non-GAAP Operating Margin Expands to 12.8%
Non-GAAP operating income was $83.7 million (12.8% margin) versus $77.0 million (11.8%) a year ago; non-GAAP diluted EPS was $2.65 versus $2.26. Free cash flow fell to $65.2 million from $89.2 million.
-
Full-Year 2026 Outlook Unchanged
Management still expects non-GAAP currency-neutral revenue of -3.0% to +0.5%, a non-GAAP operating margin of 10.0% to 12.0%, and free cash flow of $290 million to $340 million.
Analysis · BIO · Industrial Applications And Services
The headline GAAP profit is an accounting artifact, not operating strength. Of the pre-tax result, $588.2 million came from marking up the Sartorius stake, while operations actually lost $(49.7) million on $77.2 million of restructuring and a $49.8 million non-cash impairment from cutting R&D programs. Strip those out and the core business earned $83.7 million, a 12.8% non-GAAP operating margin versus 11.8% a year ago, on essentially flat revenue of $656.4 million. Growth is the real question: currency-neutral sales rose just 0.7%, Life Science fell 2.4% on weak process chromatography, and management kept a full-year outlook that still allows revenue to decline 3.0%. That unchanged guidance, against a stock trading near its 52-week high, is what investors will price.
How filings like this one have moved
In the 30 days to Nov 6, 2026, 35.2% of the 2649 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BIO was trading at $379.29 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $10.2B. The 52-week trading range was $236.73 to $396.23. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.